A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)
- Resource Type
- Article
- Source
- In
Clinical Breast Cancer April 2022 22(3):269-278 - Subject
- Language
- ISSN
- 1526-8209